《麻省理工科技评论》 第129卷 第3期 · 2026年5月刊 · 中文解读
名字背后:Moderna的“疫苗”与“疗法”之争
The Checkup: What's in a name? Moderna's 'v'
约 7 分钟Columns在小程序里点播,20 到 60 分钟做好
这篇讲什么
本文探讨了Moderna公司为避免疫苗负面联想而将其癌症mRNA产品改称为“个体化新抗原疗法”的策略及其引发的争议。
原文开头
What’s in a name? Moderna’s “vaccine” vs. “therapy” dilemma By Antonio Regalado Is it the Department of Defense or the Department of War? The Gulf of Mexico or the Gulf of America? A vaccine—or an “individualized neoantigen treatment”? That’s the Trump-era vocabulary paradox facing Moderna, the covid-19 shot maker whose plans for next-generation mRNA vaccines against flus and emerging pathogens have been dashed by vaccine skeptics in the federal government. Canceled con- tracts and unfriendly regulators have pushed the Massachusetts-based biotech firm to a breaking point. Last year, Robert F. …
摘自《麻省理工科技评论》(MIT Technology Review)第129卷 第3期 · 2026年5月刊。仅引用开头一小段供了解文章,版权归原刊所有,全文请阅读原刊。

微信扫码,在小程序里听完整版
不用登录先听一篇 · 或在微信搜索小程序 晨间信号